CD274 and prostate carcinoma: Consideration of these issues will be important for drug design since, for example, exosomal PD-L1, which drives tumor growth, has been shown to be resistant to systemic anti-PD-L1 therapy in a prostate cancer model (Poggio et al. 2019).